市場調査レポート

商品コード

1706786

PD-1阻害薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測

PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日: 2025年02月28日
発行: Transparency Market Research
ページ情報: 英文 242 Pages
納期: 2～10営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 5,795 848,156円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,287,236円

レポートPDFを同一の部署内・課内の5名の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,726,316円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.36円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

PD-1阻害薬市場- 調査範囲

TMRの調査レポート「世界のPD-1阻害薬市場」は、2025年から2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年から2035年までの世界のPD-1阻害薬市場の収益と予測を提供します。また、2025年から2035年までの世界のPD-1阻害薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、PD-1阻害薬市場を推察しました。

市場スナップショット
2024年の市場規模	414億米ドル
2035年の市場規模	2,015億米ドル
CAGR	15.5%

当レポートでは、世界のPD-1阻害薬市場の競合情勢について調査しています。世界のPD-1阻害薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界のPD-1阻害薬市場におけるプレイヤーの属性です。

市場企業-競合マトリックス（企業階層別・規模別）
市場シェア分析企業別（2024年）
企業プロファイル
- Akeso Biopharma Co., Ltd.
- Alphamab Oncology
- Amgen Inc.
- AstraZeneca
- BeiGene LTD.
- Bristol-Myers Squibb Company
- Eli Lilly and Company.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- GSK plc.
- Innovent
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Merck & Co., Inc.
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH.
- Other prominent players

図表

List of Tables

Table 01: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 02: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 03: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
Table 04: Global PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, By Region, 2020-2035
Table 05: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 06: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 07: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 08: North America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
Table 09: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 10: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 11: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 12: Europe PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
Table 13: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 14: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 15: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 16: Asia Pacific PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
Table 17: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 18: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 19: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 20: Latin America PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035
Table 21: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 22: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
Table 23: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Application, 2020-2035
Table 24: Middle East & Africa PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2020-2035

List of Figures

Figure 01: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 02: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 03: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Pembrolizumab, 2020-2035
Figure 04: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Nivolumab, 2020-2035
Figure 05: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Cemiplimab, 2020-2035
Figure 06: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Dostarlimab, 2020-2037
Figure 07: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2038
Figure 08: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 09: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 10: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Melanoma, 2020-2035
Figure 11: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hodgkin Lymphoma, 2020-2035
Figure 12: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Non-Small Cell Lung Cancer, 2020-2035
Figure 13: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Kidney Cancer, 2020-2035
Figure 14: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Stomach Cancer, 2020-2035
Figure 15: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Others, 2020-2035
Figure 16: Global PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 17: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
Figure 18: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
Figure 19: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
Figure 20: Global PD-1 Inhibitor Drugs Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
Figure 21: Global PD-1 Inhibitor Drugs Market Value Share Analysis, By Region, 2024 and 2035
Figure 22: Global PD-1 Inhibitor Drugs Market Attractiveness Analysis, By Region, 2024-2034
Figure 23: North America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
Figure 24: North America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 25: North America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 26: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 27: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 28: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 29: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 30: North America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 31: North America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
Figure 32: Europe - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
Figure 33: Europe - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 34: Europe - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 35: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 36: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 37: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 38: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 39: Europe PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 40: Europe PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
Figure 41: Asia Pacific - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
Figure 42: Asia Pacific - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 43: Asia Pacific - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 44: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 45: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 46: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 47: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 48: Asia Pacific PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 49: Asia Pacific PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
Figure 50: Latin America - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
Figure 51: Latin America - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 52: Latin America - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 53: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 54: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 55: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 56: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 57: Latin America PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 58: Latin America PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035
Figure 59: Middle East & Africa - PD-1 Inhibitor Drugs Market Value (US$ Bn) Forecast, 2020-2035
Figure 60: Middle East & Africa - PD-1 Inhibitor Drugs Market Value Share Analysis, by Country, 2024 and 2035
Figure 61: Middle East & Africa - PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Country, 2024-2034
Figure 62: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Drug Type, 2024 and 2035
Figure 63: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Drug Type, 2025-2035
Figure 64: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Application, 2024 and 2035
Figure 65: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Application, 2025-2035
Figure 66: Middle East & Africa PD-1 Inhibitor Drugs Market Value Share Analysis, by Distribution Channel, 2024 and 2035
Figure 67: Middle East & Africa PD-1 Inhibitor Drugs Market Attractiveness Analysis, by Distribution Channel, 2025-2035

Product Code: TMRGL86486

PD-1 Inhibitor Drugs Market - Scope of Report

TMR's report on the global PD-1 inhibitor drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global PD-1 inhibitor drugs market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global PD-1 inhibitor drugs market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the PD-1 inhibitor drugs market.

Market Snapshot
Market Value in 2024	US$ 41.4 Bn
Market Value in 2035	US$ 201.5 Bn
CAGR	15.5%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global PD-1 inhibitor drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global PD-1 inhibitor drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global PD-1 inhibitor drugs market.

The report delves into the competitive landscape of the global PD-1 inhibitor drugs market. Key players operating in the global PD-1 inhibitor drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global PD-1 inhibitor drugs market profiled in this report.

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

What is the sales/revenue generated by PD-1 inhibitor drugs across all regions during the forecast period?
What are the opportunities in the global PD-1 inhibitor drugs market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global PD-1 inhibitor drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global PD-1 inhibitor drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global PD-1 inhibitor drugs market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

4.1. Introduction
- 4.1.1. Segment Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, 2020-2035
- 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

5.1. Regulatory Landscape across Key Regions / Countries
5.2. PD-1 Inhibitor Drugs Market Trends
5.3. PORTER's Five Forces Analysis
5.4. PESTEL Analysis
5.5. Key Purchase Metrics for End-users
5.6. Brand and Pricing Analysis
5.7. Key Industry Events
5.8. Epidemiology by Country/Region

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Drug Type, 2020-2035
- 6.3.1. Pembrolizumab
- 6.3.2. Nivolumab
- 6.3.3. Cemiplimab
- 6.3.4. Dostarlimab
- 6.3.5. Others
6.4. Market Attractiveness By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2020-2035
- 7.3.1. Melanoma
- 7.3.2. Hodgkin Lymphoma
- 7.3.3. Non-Small Cell Lung Cancer
- 7.3.4. Kidney Cancer
- 7.3.5. Head and Neck Cancers
- 7.3.6. Stomach Cancer
- 7.3.7. Others
7.4. Market Attractiveness By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2020-2035
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

9.1. Key Findings
9.2. Market Value Forecast By Region
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

10.1. Introduction
- 10.1.1. Key Findings
10.2. Market Value Forecast By Drug Type, 2020-2035
- 10.2.1. Pembrolizumab
- 10.2.2. Nivolumab
- 10.2.3. Cemiplimab
- 10.2.4. Dostarlimab
- 10.2.5. Others
10.3. Market Value Forecast By Indication, 2020-2035
- 10.3.1. Melanoma
- 10.3.2. Hodgkin Lymphoma
- 10.3.3. Non-Small Cell Lung Cancer
- 10.3.4. Kidney Cancer
- 10.3.5. Head and Neck Cancers
- 10.3.6. Stomach Cancer
- 10.3.7. Others
10.4. Market Value Forecast By Distribution Channel, 2020-2035
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Online Pharmacies
10.5. Market Value Forecast By Country, 2020-2035
- 10.5.1. U.S.
- 10.5.2. Canada
10.6. Market Attractiveness Analysis
- 10.6.1. By Drug Type
- 10.6.2. By Indication
- 10.6.3. By Distribution Channel
- 10.6.4. By Country

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast By Drug Type, 2020-2035
- 11.2.1. Pembrolizumab
- 11.2.2. Nivolumab
- 11.2.3. Cemiplimab
- 11.2.4. Dostarlimab
- 11.2.5. Others
11.3. Market Value Forecast By Indication, 2020-2035
- 11.3.1. Melanoma
- 11.3.2. Hodgkin Lymphoma
- 11.3.3. Non-Small Cell Lung Cancer
- 11.3.4. Kidney Cancer
- 11.3.5. Head and Neck Cancers
- 11.3.6. Stomach Cancer
- 11.3.7. Others
11.4. Market Value Forecast By Distribution Channel, 2020-2035
- 11.4.1. Hospital Pharmacies
- 11.4.2. Retail Pharmacies
- 11.4.3. Online Pharmacies
11.5. Market Value Forecast By Country/Sub-region, 2020-2035
- 11.5.1. Germany
- 11.5.2. U.K.
- 11.5.3. France
- 11.5.4. Italy
- 11.5.5. Spain
- 11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
- 11.6.1. By Drug Type
- 11.6.2. By Indication
- 11.6.3. By Distribution Channel
- 11.6.4. By Country/Sub-region

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast By Drug Type, 2020-2035
- 12.2.1. Pembrolizumab
- 12.2.2. Nivolumab
- 12.2.3. Cemiplimab
- 12.2.4. Dostarlimab
- 12.2.5. Others
12.3. Market Value Forecast By Indication, 2020-2035
- 12.3.1. Melanoma
- 12.3.2. Hodgkin Lymphoma
- 12.3.3. Non-Small Cell Lung Cancer
- 12.3.4. Kidney Cancer
- 12.3.5. Head and Neck Cancers
- 12.3.6. Stomach Cancer
- 12.3.7. Others
12.4. Market Value Forecast By Distribution Channel, 2020-2035
- 12.4.1. Hospital Pharmacies
- 12.4.2. Retail Pharmacies
- 12.4.3. Online Pharmacies
12.5. Market Value Forecast By Country/Sub-region, 2020-2035
- 12.5.1. China
- 12.5.2. Japan
- 12.5.3. India
- 12.5.4. Australia & New Zealand
- 12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
- 12.6.1. By Drug Type
- 12.6.2. By Indication
- 12.6.3. By Distribution Channel
- 12.6.4. By Country/Sub-region

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast By Drug Type, 2020-2035
- 13.2.1. Pembrolizumab
- 13.2.2. Nivolumab
- 13.2.3. Cemiplimab
- 13.2.4. Dostarlimab
- 13.2.5. Others
13.3. Market Value Forecast By Indication, 2020-2035
- 13.3.1. Melanoma
- 13.3.2. Hodgkin Lymphoma
- 13.3.3. Non-Small Cell Lung Cancer
- 13.3.4. Kidney Cancer
- 13.3.5. Head and Neck Cancers
- 13.3.6. Stomach Cancer
- 13.3.7. Others
13.4. Market Value Forecast By Distribution Channel, 2020-2035
- 13.4.1. Hospital Pharmacies
- 13.4.2. Retail Pharmacies
- 13.4.3. Online Pharmacies
13.5. Market Value Forecast By Country/Sub-region, 2020-2035
- 13.5.1. Brazil
- 13.5.2. Mexico
- 13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
- 13.6.1. By Drug Type
- 13.6.2. By Indication
- 13.6.3. By Distribution Channel
- 13.6.4. By Country/Sub-region

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast By Drug Type, 2020-2035
- 14.2.1. Pembrolizumab
- 14.2.2. Nivolumab
- 14.2.3. Cemiplimab
- 14.2.4. Dostarlimab
- 14.2.5. Others
14.3. Market Value Forecast By Indication, 2020-2035
- 14.3.1. Melanoma
- 14.3.2. Hodgkin Lymphoma
- 14.3.3. Non-Small Cell Lung Cancer
- 14.3.4. Kidney Cancer
- 14.3.5. Head and Neck Cancers
- 14.3.6. Stomach Cancer
- 14.3.7. Others
14.4. Market Value Forecast By Distribution Channel, 2020-2035
- 14.4.1. Hospital Pharmacies
- 14.4.2. Retail Pharmacies
- 14.4.3. Online Pharmacies
14.5. Market Value Forecast By Country/Sub-region, 2020-2035
- 14.5.1. GCC Countries
- 14.5.2. South Africa
- 14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
- 14.6.1. By Drug Type
- 14.6.2. By Indication
- 14.6.3. By Distribution Channel
- 14.6.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2024)
15.3. Company Profiles
- 15.3.1. Akeso Biopharma Co., Ltd.
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Financial Overview
  - 15.3.1.3. Product Portfolio
  - 15.3.1.4. Business Strategies
  - 15.3.1.5. Recent Development
- 15.3.2. Alphamab Oncology
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Financial Overview
  - 15.3.2.3. Product Portfolio
  - 15.3.2.4. Business Strategies
  - 15.3.2.5. Recent Development
- 15.3.3. Amgen Inc.
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Financial Overview
  - 15.3.3.3. Product Portfolio
  - 15.3.3.4. Business Strategies
  - 15.3.3.5. Recent Development
- 15.3.4. AstraZeneca
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Financial Overview
  - 15.3.4.3. Product Portfolio
  - 15.3.4.4. Business Strategies
  - 15.3.4.5. Recent Development
- 15.3.5. BeiGene LTD.
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Financial Overview
  - 15.3.5.3. Product Portfolio
  - 15.3.5.4. Business Strategies
  - 15.3.5.5. Recent Development
- 15.3.6. Bristol-Myers Squibb Company
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Financial Overview
  - 15.3.6.3. Product Portfolio
  - 15.3.6.4. Business Strategies
  - 15.3.6.5. Recent Development
- 15.3.7. Eli Lilly and Company.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Financial Overview
  - 15.3.7.3. Product Portfolio
  - 15.3.7.4. Business Strategies
  - 15.3.7.5. Recent Development
- 15.3.8. F. Hoffmann-La Roche Ltd
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Financial Overview
  - 15.3.8.3. Product Portfolio
  - 15.3.8.4. Business Strategies
  - 15.3.8.5. Recent Development
- 15.3.9. Gilead Sciences, Inc.
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Financial Overview
  - 15.3.9.3. Product Portfolio
  - 15.3.9.4. Business Strategies
  - 15.3.9.5. Recent Development
- 15.3.10. GSK plc.
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Financial Overview
  - 15.3.10.3. Product Portfolio
  - 15.3.10.4. Business Strategies
  - 15.3.10.5. Recent Development
- 15.3.11. Innovent
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Financial Overview
  - 15.3.11.3. Product Portfolio
  - 15.3.11.4. Business Strategies
  - 15.3.11.5. Recent Development
- 15.3.12. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  - 15.3.12.1. Company Overview
  - 15.3.12.2. Financial Overview
  - 15.3.12.3. Product Portfolio
  - 15.3.12.4. Business Strategies
  - 15.3.12.5. Recent Development
- 15.3.13. Merck & Co., Inc.
  - 15.3.13.1. Company Overview
  - 15.3.13.2. Financial Overview
  - 15.3.13.3. Product Portfolio
  - 15.3.13.4. Business Strategies
  - 15.3.13.5. Recent Development
- 15.3.14. Eli Lilly and Company
  - 15.3.14.1. Company Overview
  - 15.3.14.2. Financial Overview
  - 15.3.14.3. Product Portfolio
  - 15.3.14.4. Business Strategies
  - 15.3.14.5. Recent Development
- 15.3.15. Boehringer Ingelheim International GmbH.
  - 15.3.15.1. Company Overview
  - 15.3.15.2. Financial Overview
  - 15.3.15.3. Product Portfolio
  - 15.3.15.4. Business Strategies
  - 15.3.15.5. Recent Development
- 15.3.16. Other prominent players
  - 15.3.16.1. Company Overview
  - 15.3.16.2. Financial Overview
  - 15.3.16.3. Product Portfolio
  - 15.3.16.4. Business Strategies
  - 15.3.16.5. Recent Development

PD-1阻害薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測

PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

PD-1阻害薬市場- 調査範囲

目次

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章主要洞察

第6章世界の市場分析と予測：薬剤の種類別

第7章世界の市場分析と予測：適応症別

第8章世界の市場分析と予測：流通チャネル別

第9章世界の市場分析と予測：地域別

第10章北米の市場分析と予測

第11章欧州の市場分析と予測

第12章アジア太平洋地域の市場分析と予測

第13章ラテンアメリカの市場分析と予測

第14章中東・アフリカの市場分析と予測

第15章競合情勢

List of Tables

List of Figures

PD-1 Inhibitor Drugs Market - Scope of Report

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

5. Key Insights

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

15. Competition Landscape

PD-1阻害薬市場：世界の産業分析、規模、シェア、成長、動向、2025-2035年予測

PD-1 Inhibitor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

PD-1阻害薬市場- 調査範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー： 世界市場

第4章 市場概要

第5章 主要洞察

第6章 世界の市場分析と予測：薬剤の種類別

第7章 世界の市場分析と予測：適応症別

第8章 世界の市場分析と予測：流通チャネル別

第9章 世界の市場分析と予測：地域別

第10章 北米の市場分析と予測

第11章 欧州の市場分析と予測

第12章 アジア太平洋地域の市場分析と予測

第13章 ラテンアメリカの市場分析と予測

第14章 中東・アフリカの市場分析と予測

第15章 競合情勢

List of Tables

List of Figures

PD-1 Inhibitor Drugs Market - Scope of Report

Key Questions Answered in Global PD-1 inhibitor drugs Market Report:

PD-1 Inhibitor Drugs Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary : Global PD-1 Inhibitor Drugs Market

4. Market Overview

5. Key Insights

6. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Drug Type

7. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Indication

8. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Distribution Channel

9. Global PD-1 Inhibitor Drugs Market Analysis and Forecasts, By Region

10. North America PD-1 Inhibitor Drugs Market Analysis and Forecast

11. Europe PD-1 Inhibitor Drugs Market Analysis and Forecast

12. Asia Pacific PD-1 Inhibitor Drugs Market Analysis and Forecast

13. Latin America PD-1 Inhibitor Drugs Market Analysis and Forecast

14. Middle East & Africa PD-1 Inhibitor Drugs Market Analysis and Forecast

15. Competition Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章主要洞察

第6章世界の市場分析と予測：薬剤の種類別

第7章世界の市場分析と予測：適応症別

第8章世界の市場分析と予測：流通チャネル別

第9章世界の市場分析と予測：地域別

第10章北米の市場分析と予測

第11章欧州の市場分析と予測

第12章アジア太平洋地域の市場分析と予測

第13章ラテンアメリカの市場分析と予測

第14章中東・アフリカの市場分析と予測

第15章競合情勢